Member Info for Burble

Bermuda.

No comment ;-)

Hi Debs,

No I hadn’t thought of regional/local newspapers. But that is a good idea. I’ll drop them a line tomorrow and see whether it’s on their radar.

When there has been publication in national newspapers on cancer vaccines, Covid vaccines, second gen trials, variant proof vaccines, DNA vaccines, t-cells etc I have emailed a number of journalists highlighting Scancell’ track record, products and trials both past, present and future.

I generally have got a positive response thanking me. Occasionally I have received follow up emails further down the line asking for further information or for heads up of new developments in the field.

National newspapers definitely have Scancell on their radar. Myself and others have been highlighting this from both a Covidity, SCIB1, MODI-1 and general T-cell angle.

BOJO

Definitely! In all aspects of life they say knowledge is key.

This is a good article to read explaining some of this. https://www.nature.com/articles/s41565-021-00946-9 - specifically the section entitled 'The case of adenoviruses'

Ivy,

There will undoubtedly be an immune response against the vector - as a foreign body within the patient, it is highly likely that the patient develops an immune response targetting the vector. Obviously many adenovirus strains may be deployed, but it is a phenomenon that is seen with this type of vaccine delivery system. There are ways this can be minimised through things like surface engineering, but it still is a possibility which isn't faced with other delivery mechanisms.

Some of the older papers on this saw that when an adenovirus vector was delivered intramuscularly, a neutralising antibody response peaked between two to three weeks after delivery. Interesting, this neutralising effect was only prohibitive of successful delivery when delivered intravenously not intramuscularly. One of the other things that is a compounding factor is background anti-adenovirus immunity. Hence why generally the viruses used are non-human as there is then limited chance of there being pre-existing immunity.

Slightly different target, but the same goes for oncolytic virus therapy. Repeated cycles of enadenotucirev (a group B adenovirus) was conducted in clinical trials. This found that activity of the virus was lower with each repeat cycle (https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0510-7) 'However, the virus activity was lower at cycle 2 than cycle 1 and declined further by cycle 3, suggesting that the overall affinity of the antibody response might be increasing, leading to an increase in overall neutralizing activity. However, it is not known whether, or to what extent these antibodies may interfere with virus delivery to and activity within tumors.'

Whilst the world does need better vaccines, it is important to note the benefits of different platform technologies. Immunity Bio bases it's vaccines on a human adenovirus platform - similar to the astra zeneca vaccine. Whilst this has benefits over mRNA vaccines for things like cold chain storage, size of genetic material delivered etc. It does have drawbacks if there is requirement to repeat dose as the body mounts an immune response against the vector leading to reductions in efficacy.

Nucleotide based vaccines (mRNA or DNA) do not have this drawback. So whilst the world needs multiple vaccines, if we see waining immunity even in these second generation vaccines, IMHO I think there is more likelihood of the world coalescing behind second generation boosters based on mRNA or DNA technology than they will on adenovirus based platforms. So SCLP has plenty of opportunities for a shot at goal with Covidity, even in an ever increasingly crowded field.

Roses - I suspected the same. She exuded confidence in her own inventions. I suspect she may have got carried away a bit, but hey - I'm not complainin!

Miavoce

Which is interesting given she also said BioNTech were partners for SCIB2. I wonder whether there is acknowledgements that mRNA vaccines may be a temporary fix and that BioNTech may need to look for something a bit more robust and sustainable. Obv from a financial perspective mRNA vaccines are a cashcow, but they're unsustainable in the long run if they only last 6 months at a time. As we've shown with SCIB1, the efficacy of DNA vaccines can last far longer....

Hasiba,

Not a problem in the slightest. :)

Did we already know that SCIB2 was partnered with BioNTech AND CRUK?

Correction: Week, not day

That's helpful and logical. LD's response to asking whether recruitment was slow was 'we needed safety data, so the initial few patients we had to wait a few days before we could dose the next. We are now recruiting at a dozen a day and have seen no safety issues so far.

You might be right on those fronts. I wonder whether there is problems with people wanting to hold out and get dosed with Pfizer/AZ/other approved Covid vaccines rather than participate in trials.

ViolinDog - yes only 14/40 patients dosed so far. That is both frustrating and worrying - I wonder what the delays are.

I've just received an email from my broker asking for my vote on the EGM to be held on the 15th December. Have I missed something, or was this included in the recent placing RNS?

Crumbs

I agree data will be king here. It wouldn’t surprise me though if the team will be rapidly making and testing the Omicrom spike protein in new lab test. One would assume that they have still banked samples from previous Covidity tested mouse models. It wouldn’t be too difficult to run some of those on new variant material to see whether they’re reactive. I have every faith that LD and team are astute enough to stay one step ahead of the game on this front.

Whilst worrying, this could play into our hands. Especially if LD and team are ahead of the game and able to use patient blood samples to test against this new variant. Would be interesting to see what evolves over the next few weeks/months.

Looking at the slide deck, has anyone noticed that there is a new logo top right on the slide deck. Different colours than the normal Scancell logo. I'm curious as to what that is about, seeing as it doesn't appear in 2019 and is hidden on the 2020 one by the speaker as it was a digital event last year.

It's not on the slide deck for the presentation to LSX World Congress February 2020.

Standard logo = orange, grey, turquoise.
Additional logo = blue, grey, turquoise.

Could this be the logo for Zakari therapeutics?